I

Intuitive Surgical

Builds robots for minimally invasive surgery

Project Manager - Advanced Tissue Models

Full-Time
$121.6k - $205.9k/yr+ Incentives + Equity
Senior
Bachelor's, Master's
Durham, NC, USA
In PersonTravel up to 10% is required. Preference is given to candidates who do not reside or plan to reside in the listed states.
Project & Program ManagementProject Management

About the job

Requirements
  • At least 5 years of experience in project management, preferably in new product development and commercialization.
  • Experience leading complex projects in medical device, engineering, or other clinical fields.
  • Proven ability to oversee new product development through Design Controls and demonstrated success supporting product launches.
  • Strategic thinking, strong business and financial acumen, and demonstrated experience in data-driven decision-making.
  • Exceptional communication and influencing ability, with a track record of cross-functional collaboration to ensure project success.
  • Experience working with key opinion leaders, healthcare stakeholders, and executives, with the ability to present tailored information clearly and concisely to various leadership audiences.
  • Ability to thrive in fast-paced, ambiguous, high-growth environments.
  • Ability to lead multiple projects simultaneously and handle ambiguity.
  • Ability to travel up to 10%.
  • A BS degree in engineering, business, health sciences, or another scientific field.
Responsibilities
  • Lead cross-functional teams for new product development and product revision efforts.
  • Monitor projects from initiation through delivery and post-launch customer support activities.
  • Create and maintain project plans, dashboards, and schedules.
  • Develop and monitor project budgets.
  • Ensure projects adhere to the Advanced Tissue Models Design Control process and lead phase-gate activities.
  • Organize cross-functional activities to ensure project completion, including product delivery on schedule and within budget constraints.
  • Organize and manage team meetings, design reviews, and phase-gate exit review boards.
  • Participate in portfolio reviews and provide clear project updates, including status, risks, and mitigations.
  • Support the definition and alignment of project goals with business-unit and corporate objectives.
  • Organize and prioritize team work to accomplish project objectives.
  • Support team members, including functional managers across the business, in planning and executing activities required to achieve project goals.
  • Support resource-demand planning for project teams, including estimating project work efforts, needs, roles, and responsibilities.
  • Work with Operations and Manufacturing to determine strategies for product cut-ins.
  • Work with Logistics, Regulatory, and Customer Training to determine the global distribution plan.
  • Support product management with requirements development, go-to-market, and post-launch activities.
  • Coordinate and communicate with other project managers and core teams leading new solution or new indication development with Advanced Tissue Models dependencies to align project goals, priorities, scope, resources, budget, and timelines.
  • Maintain the Advanced Tissue Models project-management ecosystem, facilitate best practices, and drive process improvements.
  • Perform additional job duties and tasks as determined by the functional people manager.
Desired Qualifications
  • A master’s degree.
  • Certification in project management, such as Project Management Professional (PMP).
  • Experience in medical device or other regulated industries.
  • Experience in or certification in change management and negotiation.
  • Experience supporting product launches for multiple markets and working with Regulatory, Global Trade, and Logistics teams to ensure successful global product distribution.

About the company

Intuitive Surgical makes da Vinci robots that let surgeons operate through a few small incisions, and Ion, a robot that reaches deep into the lungs to take tissue samples. In 2000, da Vinci became the first robotic system cleared by the FDA for general laparoscopic surgery, meaning keyhole operations in the abdomen. A surgeon sits at a nearby console and steers robotic arms holding a 3D camera and wristed instruments, which turn hand movements into smaller, steadier motions. Hospitals buy or lease the robots, then keep paying for the instruments used in each operation and for service. Intuitive was founded in 1995 to commercialize robotic surgery research from SRI International and is based in Sunnyvale, California.

Company Size

10,001+

Company Stage

IPO

Headquarters

Sunnyvale, California

Founded

1995

Get referred to Intuitive Surgical

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Demand keeps compounding: da Vinci procedures grew 15% and revenue 19%, to $2.89 billion, in the June 2026 quarter.
  • Room to grow: Intuitive listed 748 open roles in October 2026, including 191 in engineering and 312 in Sunnyvale.
  • Repeat sales steady the business: instruments and service made 76% of revenue in the June 2026 quarter.

What critics are saying

  • Stock grants have shrunk: shares fell 27% from January to October 2026, versus 9% for rival Medtronic.
  • Device giants are moving in: the FDA cleared rival robots from Medtronic in December 2025 and J&J in July 2026.
  • Instrument sales face a court fight: in August 2026, an appeals court revived a repair firm's monopoly suit against Intuitive.

What makes Intuitive Surgical unique

  • Hospitals rent more than they buy: 254 of 468 da Vinci systems placed in the June 2026 quarter were leases.
  • It runs without borrowing: Intuitive had no debt and $8.6 billion in cash and investments in June 2026.
  • Its CEO is a 30-year insider: Dave Rosa, CEO since July 2025, joined as employee number nine in 1996.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Hybrid Work Options

Growth & Insights and Company News

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Oct 26th, 2026
Intuitive Surgical trades at 40x earnings, but forecast profit of $4.55B in 2027 cuts it to 34.7x

Intuitive Surgical (ISRG), maker of da Vinci surgical robots, trades at 40.0 times adjusted earnings over the last twelve months. Against forecast profit, the multiple looks lower: its $158 billion market value is 39.5 times expected fiscal 2026 net income of $3.99 billion, and 34.7 times fiscal 2027 net income of $4.55 billion. Consensus puts fiscal 2027 revenue at $13.3 billion, up 12.1%, slower than the 20.5% growth of the last twelve months. The forecast net margin of 34.1% is close to the 34% the company kept over that period. Risks include instrument pricing cuts of about 3% to 5% per procedure and higher spending. Management will give operating expense guidance in January.

LinkedIn
Oct 25th, 2026
Ruby Robotics Acquired by Intuitive for Minimally Invasive Care Solutions | Ruby Robotics posted on the topic | LinkedIn

We are excited to announce that in late 2025, Ruby Robotics was acquired by Intuitive, a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery.   Together with Intuitive, we are continuing our mission to improve the accuracy, efficiency, and accessibility of tissue assessment during biopsy procedures at the point of care with integrated robotics and artificial intelligence solutions.   Thank you to our team, investors, advisors, consultants, and contributors whose shared belief in our vision made Ruby a success. To our new Intuitive colleagues: we’re excited to collaborate with you and look forward to making a positive impact on patients and physicians together. E14 Fund Root Ventures Link Ventures SeedFolio Kicker Ventures Celtic House Asia Partners Zelda Ventures Tamer Capital Taiwan Global Angels Cendana Capital UNION | 19 comments on LinkedIn

Yahoo Finance
Oct 1st, 2026
Intuitive Surgical down 30% in 2026, but Wall Street analysts stay bullish

Intuitive Surgical has lost nearly 30% year-to-date in 2026, making it one of healthcare's biggest losers. The stock fell over 40% by late July. Despite this decline, Wall Street remains bullish—24 of 32 analysts surveyed by S&P Global in September rated it a "buy" or "strong buy." The medical device maker faces several challenges. Growth is slowing whilst the stock trades at a forward price-to-earnings multiple over 33. Competition in China remains difficult, and the company now battles healthcare giants Johnson & Johnson, Medtronic, and Stryker in robotic surgical systems. The expiration of Affordable Care Act subsidies and rising GLP-1 drug usage have also impacted procedure volumes. However, the company's Asian revenue still jumped 20% year-over-year in Q2, suggesting these headwinds aren't insurmountable.

Yahoo Finance
Sep 17th, 2026
Intuitive Surgical, IonQ, and Accenture hold billions in net cash for growth

Investors seeking financial stability often look to companies with more cash than debt, as these businesses have greater flexibility for growth investments, buybacks, and dividends. Intuitive Surgical holds $5.22 billion in net cash. The robotic surgery pioneer achieved 20.7% annual revenue growth over the past two years, whilst its earnings per share increased 17.4% annually over five years. IonQ maintains $2.06 billion in net cash, representing 14.1% of its market capitalisation. The quantum computing company posted 181% annual revenue growth over two years and expects 163% growth next year. Accenture has $1.78 billion in net cash. The professional services firm employs approximately 774,000 people across more than 120 countries. Companies with strong balance sheets can navigate uncertain markets whilst pursuing expansion opportunities without the burden of significant debt obligations.

Yahoo Finance
Aug 23rd, 2026
Thermo Fisher vs Intuitive Surgical: which premium healthcare stock justifies valuation?

Thermo Fisher and Intuitive Surgical both delivered strong recent quarters, but their premium valuations rest on different foundations. Thermo Fisher's case depends on recovery in life sciences spending after the pandemic slowdown. The company's Life Sciences Solutions segment saw reported revenue climb 13% year-over-year, with organic revenue up 3%. The Analytical Instruments business returned to growth after nearly two years of weak demand, suggesting laboratory spending is normalising. Intuitive Surgical maintains its premium through business model strength. The company's non-GAAP gross profit margin reached 70.0%, whilst its non-GAAP operating margin expanded 330 basis points year-over-year to 42.1%. Recurring revenue streams constitute roughly 85% of total sales. Intuitive placed 468 da Vinci surgical units in fiscal Q2, marking 18% year-over-year growth, indicating continued hospital investment in robotic surgery platforms.